We are live on ! Find out more
BMY.RT

Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT

Delisted

BMY.RT was delisted on the 31st of December, 2020.

Back to rankings

12 hedge funds and large institutions have $5.25M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 529 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

98% less funds holding

Funds holding: 546 → 12 (-534)

98% less capital invested

Capital invested by funds: $338M → $5.25M (-$333M)

100% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 529

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

Holders
12
Holders Change
-534
Holders Change %
-97.8%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
529
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
JCI
Jet Capital Investors
New York
+$2.15M
2
TNB
Thomasville National Bank
Georgia
+$146K

Top Sellers

1
PCM
Pentwater Capital Management
Florida
-$47.7M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$20.6M
3
ACM
Abrams Capital Management
Massachusetts
-$17.1M
4
FCM
Farallon Capital Management
California
-$14.8M
5
BFS
Bard Financial Services
Connecticut
-$13.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
FFW
426
Fusion Family Wealth
New York
– -$1K -685 Closed
BCWM
427
Bartlett & Co Wealth Management
Ohio
– -$380 -550 Closed
FP
428
Financial Perspectives
Minnesota
– -$338 -490 Closed
TFIPS
429
Towarzystwo Funduszy Inwestycyjnych PZU SA
– -$303 -439 Closed
ECM
430
Estabrook Capital Management
New York
– -$207 -300 Closed
GI
431
Gradient Investments
Minnesota
– -$1K -281 Closed
PB
432
Pinnacle Bancorp
Nebraska
– -$1K -258 Closed
MFM
433
MD Financial Management
Ontario, Canada
– -$1K -95 Closed
TFGT
434
TS Financial Group (TSFG)
Illinois
– -$1K -48 Closed
ED
435
Exane Derivatives
France
– -$19 -28 Closed
14 15 16 17
18

BMY.RT Hedge Fund Activity: Q1 2021 in Review

12 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q1 2021, worth a combined $5.25M — down 98% from $338M a quarter earlier.

Sellers outnumbered buyers: 529 funds closed out of BMY.RT and 2 opened new positions — a net loss of 527 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Jet Capital Investors, adding an estimated $2.15M. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $47.7M sold.

  • 12 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q1 2021, down from 546 in Q4 2020.
  • Funds reported $5.25M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q1 2021, down 98% quarter-over-quarter.
  • 2 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q1 2021 and 529 closed out, a net change of -527 holders.
  • The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q1 2021 was Jet Capital Investors, an estimated $2.15M added.
  • The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q1 2021 was Pentwater Capital Management, an estimated $47.7M sold.

Based on aggregated 13F filings for Q1 2021.